Printer Friendly

CStone receives CNDA approval for anti-CTLA-4 antibody CS1002.

M2 PHARMA-August 28, 2018-CStone receives CNDA approval for anti-CTLA-4 antibody CS1002


Biopharmaceutical company CStone Pharmaceuticals (CStone) reported on Monday the receipt of approval from the China National Drug Administration (CNDA) for its IND application for the investigational cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) monoclonal antibody,CS1002.

To date, the company has built a portfolio of 14 oncology products, eight of which are at clinical development stage, including three in registration studies.

According to the company, Cytotoxic T lymphocyte associated antigen 4 (CTLA-4), also known as CD152, is a transmembrane protein encoded by the CTLA-4 gene that can down-regulate the activity of T cells when binding with its ligands, B7.1 and B7.2, a pathway used by tumour cells to avoid T lymphocyte attack. Consequently, blockade of the CTLA-4 pathway can stimulate T cell activation and proliferation to induce or enhance anti-tumour immune responses.

CTLA-4 provides a new immuno-therapeutic approach to a number of diseases, including tumors, stated the company.

The company added that Bristol-Myers Squibb's Yervoy (ipilimumab) is currently the only anti-CTLA-4 antibody to gain a market approval worldwide, although Yervoy has not yet been approved in China. Pre-clinical tests have shown that CS1002 has a relatively strong affinity to CTLA-4 and is expected to match Yervoy in terms of efficacy.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 28, 2018
Previous Article:Brain Research Foundation (BRF) selects two projects to help identify new treatments to reduce opioid relapse.
Next Article:Pharma Logistics offers TACHC members with return credit services.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |